Does FDA Rejection Of Label Warning Shield Manufacturers From Tort Suits?

US Supreme Court asks Solicitor General to weigh in on Merck petition requesting clarification of its Wyeth v. Levine ruling; Third Circuit says decision is 'cryptic and open-ended.'

US Supreme court building with 1st statue on left

The US Supreme Court could revisit its landmark ruling in Wyeth v. Levine that FDA-approved labeling does not block individuals from filing personal injury suits against pharma companies under state law. Merck has asked the court to specify that a drug manufacturer cannot be subject to failure-to-warn claims about a risk associated with its product if it informs FDA about the risk and the agency rejects adding it to the drug's label.

In its Dec. 4 orders, the court invited the Solicitor General to convey the US government's views on Merck...

More from Legal & IP

More from Pink Sheet